Erythromyacin antibiotic product, use and formulation thereof
US6663891B2 · kind B2 · utility
32Cited by
33References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2001 |
| Grant date | Dec 16, 2003 |
| Priority date | — |
| Expiry date | Jun 28, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An antibiotic product, in particular an erythromyacin, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.